Roche signs $1.2B partnership with China’s Rona for obesity drug as Stryker pours $400M into CMR Surgical

Roche has entered a $1.2 billion agreement with Chinese firm Rona to advance an obesity treatment, targeting the growing market for weight‑loss therapies in China.

The deal will combine Roche’s drug development capabilities with Rona’s local commercial expertise, aiming to accelerate patient access across the region.

In a separate move, medical‑device company Stryker disclosed a $400 million investment in CMR Surgical, supporting the latter’s development of robotic surgery platforms.